LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Secures Zegfrovy Rights In $1.5 Billion Dizal Deal
AstraZeneca (LSE:AZN) has secured global rights to Zegfrovy (sunvozertinib) from Dizal.
The agreement covers an already approved therapy for certain non small cell lung cancer patients with EGFR exon 20 insertion mutations.
The deal includes financial terms tied to the asset and follows recent positive clinical data shared at a major oncology meeting.
The move expands AstraZeneca's oncology portfolio and deepens its research presence in China.
AstraZeneca, listed as LSE:AZN, is adding...